TABLE 2.

Six working groups developing specific topics considered in the ICPs.

Group 1	Diagnostic measures
	Charlotte G Mørtz et al.
	To discuss treatment targets based on clinical scores versus symptoms and markers of quality of life with a focus on the feasibility in a daily practice setting considering geographical variations of healthcare systems
Group 2	Topical treatment
	Andreas Wollenberg et al.
	To discuss indications and practicalities as recommended by the guidelines, transitioning points to systemic therapies and the current quality and needs of healthcare provision of topical treatment in AD considering geographical differences
Group 3	Systemic treatment
	Thomas Werfel et al.
	To discuss indications for systemic therapies in different patient subgroups and age groups, availability of approved and reimbursed therapies with country‐specific differences as well as the role of off‐label drugs
Group 4	Comorbidities
	Wojciech Francuzik et al.
	To discuss atopic and non‐atopic comorbidities and their impact on disease burden and treatment options
Group 5	Ocular comorbidities
	Marjolein de Bruin‐Weller et al.
	To discuss the risk of ocular involvement in AD, its assessment and management as well as referral criteria to the ophthalmologist
Group 6	ICP by digital harmonisation
	Jean Bousquet
	To discuss digitally‐supported ICPs as part of a patient‐centred approach linking patients, pharmacists and physicians, and an opportunity to lead to a more rapid diagnosis, to guide stepwise treatment in everyday life and to collect patients' feedback